Pegargiminase
- Generic Name
- Pegargiminase
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 1394129-74-8
- Unique Ingredient Identifier
- 0B7PYQ9YRT
- Background
Pegargiminase is an anticancer agent.
- Indication
Investigated for use/treatment in melanoma and hepatocellular carcinoma.
- Associated Conditions
- -
- Associated Therapies
- -
Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)
- Conditions
- Interventions
- First Posted Date
- 2023-10-17
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT06085729
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Phase 2 Study of ADI-PEG 20 Plus Lenvatinib Treatment in Subjects With Unresectable Hepatocellular Carcinoma
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Chang Gung Memorial Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT06034977
- Locations
- 🇨🇳
Chang Gung Memorial Hospital, Linkou branch, Taoyuan, Taiwan
A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT06006286
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Study of ADI-PEG 20 Versus Placebo in Subjects With NASH
- Conditions
- Interventions
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- Polaris Group
- Target Recruit Count
- 40
- Registration Number
- NCT05842512
- Locations
- 🇨🇳
Chang Gung Medical Foundation-Linkou (CGMF-LK), Taoyuan, Taiwan
🇨🇳Kaohsiung Medical University Chung-Ho Memorial Hospital(KMUH), Kaohsiung, Taiwan
🇨🇳Chang Gung Medical Foundation-Kaohsiung (CGMF-KS), Kaohsiung, Taiwan
ADI-PEG20, Obesity and Prediabetes
- First Posted Date
- 2023-04-25
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 48
- Registration Number
- NCT05829239
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers
- Conditions
- Interventions
- First Posted Date
- 2022-11-15
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 114
- Registration Number
- NCT05616624
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Inova Schar Cancer Institute, Fairfax, Virginia, United States
Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-04-08
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- Polaris Group
- Target Recruit Count
- 300
- Registration Number
- NCT05317819
- Locations
- 🇨🇳
Changhua Christian Hospital (CCH), Changhua, Taiwan
🇨🇳Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH), Kaohsiung, Taiwan
🇨🇳Chi Mei Hospital, Liouying (CMMC-LY), Tainan, Taiwan
Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia
- First Posted Date
- 2021-08-12
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Polaris Group
- Target Recruit Count
- 60
- Registration Number
- NCT05001828
- Locations
- 🇺🇸
Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸Orchard Healthcare Research Inc, Skokie, Illinois, United States
🇺🇸Levine Cancer Institute, Charlotte, North Carolina, United States
ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects with Glioblastoma Multiforme
- Conditions
- Interventions
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Polaris Group
- Target Recruit Count
- 100
- Registration Number
- NCT04587830
- Locations
- 🇰🇷
Chonnam National University Hwasun Hospital, Hwasun-gun, Jeollanam-do, Korea, Republic of
🇰🇷Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of
🇰🇷Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Seocho-gu, Korea, Republic of
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
- First Posted Date
- 2019-05-31
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Global Coalition for Adaptive Research
- Target Recruit Count
- 1030
- Registration Number
- NCT03970447
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸University of California, San Diego, La Jolla, California, United States
🇺🇸Cedars Sinai - Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.